Semaglutide tablets or injections: what actually changes between the two forms?

Do the tablet and the injection use the same dose ladder?

No, and this surprises a lot of people. The Wegovy injection climbs through five dose stages (0.25mg, 0.5mg, 1.0mg, 1.7mg, and 2.4mg weekly) with each step held for roughly four weeks under prescriber guidance. The Wegovy tablet follows a separate schedule entirely: 1.5mg daily to start, then 4mg, then 9mg, arriving at a 25mg maintenance dose. The numbers look very different because oral bioavailability of semaglutide is much lower than subcutaneous delivery, the tablet needs the higher dose to achieve comparable blood levels.

One practical consequence: a patient already established on the 2.4mg weekly injection who wants to switch to the tablet can move directly to the 25mg maintenance dose, subject to prescriber agreement. Going the other direction works similarly. If you're weighing up the tablet versus the injection as starting options, the dose ladder is worth factoring in because nausea during titration behaves slightly differently between the two routes.

Neither dose schedule should be self-managed. The prescriber sets pace, and the Patient Information Leaflet is the definitive source for missed-dose and titration detail, not forum advice.

Does the way you take the tablet actually matter that much?

More than most people expect. The tablet must be taken first thing in the morning on an empty stomach, with no more than a small sip of plain water. You then wait a minimum of 30 minutes before eating, drinking anything else (yes, that includes your morning coffee), or taking other oral medicines. Miss that window and absorption drops significantly.

That 30-minute gap is the main behavioural ask the tablet places on you. For some people it slots in easily, the tablet is out before the kettle boils, and the wait is just the morning routine. For others, shift work, young children, or medicines that can't be delayed make it genuinely awkward. The injection, by contrast, can be taken on any day of the week at any time of day that suits you, with food or without.

Storage is meaningfully different too. The injection pen needs refrigeration between 2°C and 8°C, whereas the tablet stores at room temperature, no fridge required. That makes the tablet considerably more convenient for travel. For detail on the exact storage windows per form, the Mounjaro and Wegovy SmPCs on the eMC are the authoritative source.

Is the weight loss actually comparable between the two forms?

Broadly, yes, though not identically. The Wegovy injection produced around 15% average body-weight reduction over 68 weeks in the STEP 1 trial. The Wegovy tablet, in the OASIS 4 phase 3 trial (64 weeks, 307 adults with obesity or overweight plus at least one weight-related condition), showed approximately 13.6% average weight loss versus around 2.4% with placebo. Among participants who adhered fully to the regimen, the figure was closer to 17%. That fuller picture is covered in more depth if you want to compare the effectiveness data side by side.

The most common side effects in OASIS 4 were gastrointestinal (nausea, loose stools, vomiting) reported in about 74% of tablet participants versus 42% in the placebo group. The injection carries a similar GI profile. Both are typically most noticeable when a new dose stage starts, settling within days to a couple of weeks for most people. The NHS medicines page for semaglutide lists the full side-effect profile for both forms in plain language.

Head-to-head data between the two semaglutide forms in a single randomised trial don't yet exist, so direct comparisons carry uncertainty. Many people find it helpful to read whether semaglutide tablets are as good as the injections before deciding which route to explore with a clinician. Our clinical team at nume

Sorry, our clinical team at the nume prescribing team reviews every case personally before any treatment is recommended.

Who can be prescribed each form in the UK?

The licensed eligibility criteria are similar but not identical. The injection (Wegovy) is licensed for adults with a BMI of 30 or above, or 27 to 29.9 with at least one weight-related condition such as high blood pressure, high cholesterol or type 2 diabetes. The tablet shares that same lower eligibility band. Both are prescription-only medicines, which means a clinician must assess you before any supply, that assessment covers your BMI, medical history, current medicines and contraindications.

Neither form is licensed for use in pregnancy, breastfeeding, or in people who are actively trying to conceive. They are also not licensed for under-18s. People with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 cannot use either form. These exclusions are non-negotiable and form part of every clinical review.

The Wegovy tablet is not yet available on the NHS, a NICE appraisal would be needed first. The injection is available via NHS specialist weight management services under NICE TA875, though waiting times are often long. If you're considering the private route and want to understand what an assessment involves, our Wegovy tablet page covers the full picture, or you can explore our treatment options overview to see where semaglutide fits alongside other licensed medicines.

For cost context across the private market, our guide to sourcing semaglutide tablets in the UK explains what legitimate pricing looks like and what red flags to watch for. If you'd like a prescriber to review your specific situation, and you're still unsure which form suits you, our page on whether semaglutide tablets are better than injections may help you frame the right questions before your consultation. Start your free consultation and a GPhC-registered Independent Prescriber will go through your answers the same day.